(Alliance News) - GlaxoSmithKline PLC announced on Wednesday promoted Tony Wood to chief scientific officer designate, as its current CSO is set to become of chief executive of a new biotech firm in California.
The London-based pharmaceutical company said that Wood will take full responsibility for research & development at GSK from the current chief scientific officer, Hal Barron, on August 1.
Wood is currently senior vice president of Medicinal Science & Technology at GSK and is responsible for all science and technology platforms supporting the discovery, clinical development and delivery of new medicines.
Wood joined the company in 2017 from New York-based pharmaceutical company Pfizer Inc.
The company continued that, during his time at GSK, Wood has been instrumental in delivering new product launches such as its severe asthma treatment Nucala, its myeloma treatment Blenrep, and its endometrial cancer treatment Jemperli.
After Wood becomes CSO, Barron will remain a member of GSK's board, transitioning to non-executive director for an initial period of three years. As an executive, Barron has been hired away to be chief executive officer and co-chair of Altos Labs Inc in August. Altos Labs is a new private biotechnology company focused on cellular rejuvenation and is based in San Francisco.
Shares in GlaxoSmithKline were down 1.5% at 1,676.60 pence on Wednesday morning in London.
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
